Ingredient or product comparison
GHK-Cu Scalp Inflammation Mechanism: Treatment Comparison
GHK-Cu (topical peptide) NFκB suppression + TGF-β modulation Cytokine gene transcription block 4–6 weeks for cytokine reduction, 8–12 weeks for clinical improvement No follicular atrophy, no rebound inflammation. Safe for long-term use Most mechanistically tar
This source-based comparison does not add ratings or recommend a winner.
- GHK-Cu (topical peptide)
- NFκB suppression + TGF-β modulation
- Cytokine gene transcription block
- 4–6 weeks for cytokine reduction, 8–12 weeks for clinical improvement
- No follicular atrophy, no rebound inflammation. Safe for long-term use
- Most mechanistically targeted option for cytokine-driven scalp inflammation without systemic effects
- Topical corticosteroids (clobetasol, betamethasone)
- Glucocorticoid receptor activation → broad immune suppression
- Non-specific suppression of all inflammatory pathways
- 1–2 weeks for symptom reduction
- Risk of follicular atrophy, telangiectasia, and rebound flare after discontinuation
- Effective short-term, unsuitable for chronic use due to tissue damage
- Ketoconazole 2% shampoo
- Antifungal + mild anti-androgen effect
- Indirect: reduces Malassezia colonization and secondary inflammation
- 2–4 weeks for seborrheic dermatitis improvement
- Generally safe, minimal follicular impact
- Best for inflammation secondary to fungal overgrowth, limited effect on cytokine-driven inflammation
- Minoxidil 5% + tretinoin 0.025%
- Vasodilation + increased cell turnover
- Indirect: improved follicular environment may reduce inflammatory signaling
- 8–16 weeks (growth phase dependent)
- Tretinoin can cause initial irritation; minoxidil itself has minimal anti-inflammatory effect
- Promotes growth but doesn't address underlying cytokine pathways
- Oral finasteride 1mg
- 5α-reductase inhibition → reduced DHT
- Indirect: reduces DHT-triggered cytokine release
- 12–24 weeks for inflammatory marker reduction
- Systemic hormonal effects, sexual side effects in 2–4% of users
- Addresses upstream androgen trigger but not the cytokine amplification loop